Companies › Shanghai Guangsheng Biopharmaceutical
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cosiporfin Sodium for Injection (DVDMS) Photosensitizer; generates reactive oxygen species upon light activation for photodynamic | – | Phase 2 | Biliary Tract Cancers (BTC) | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07398339 | Cosiporfin Sodium for Injection (DVDMS) | Phase 2 | Biliary Tract Cancers (BTC) | Oncology | Mar 2027 |
No annotated target.
–
VIVUS Panbela Therapeutics Apollomics Elevar Therapeutics Zenith Epigenetics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.